LAS VEGAS, Nev. (702 Times, NV Globe) – In Alzheimer’s research, there are noteworthy developments. The FDA has granted expedited clearance to a ground-breaking drug that may help delay the onset of memory loss and other dementia symptoms.
“I would forget a first name or I had a number I was using just 20 minutes ago and then it would pop back and whatever,” Bob Lathrop, a drug trial patient, said.
68-year-old Lathrop is concerned that, given a history of dementia in his family, he may be headed down the same path. He so registered to take part in the lecanemab clinical trials of a potential new medication.
“One of the benefits of the volunteer situation is that I get really, really tested, Lathrop said with a chuckle.
One of the most crucial examinations for the research was passed by him. His brain MRI revealed an amyloid protein buildup, which experts believe may one day lead to aberrant cells that cause Alzheimer’s or dementia. Lecanemab has shown to get rid of amyloid that has built up.
“So the thought is by removing the amyloid protein we can actually delay the progression of the disease,” neurologist Doctor Charles Bernick with the Cleveland Clinic said.
Credits: 8 News Now
Copyright 2023 702 Times, NV Globe. All rights reserved.
- Sparks Man Arrested for Murder of 17-Year-Old Boy - November 29, 2023
- Washoe County School District Approves New Puberty Videos for Fourth Graders - November 29, 2023
- Teenager Arrested in Las Vegas for Making Terroristic Threats - November 29, 2023